Linked Life Data

19322063

Source:http://linkedlifedata.com/resource/pubmed/id/19322063

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
2009-3-26
pubmed:abstractText
Glucocorticoid therapy is widely used in clinical practice. However, treatment with steroids carries the risk of side effects. We investigated changes in serum adiponectin and leptin in response to systemic glucocorticoid treatment in 18 pediatric patients with inflammatory bowel disease and contrasted these findings to circulating glucocorticoid bioactivity measured with a mammalian cell bioassay. Interestingly, serum adiponectin levels at 2 to 4 weeks of therapy were significantly higher in patients who experienced acute glucocorticoid-related side effects (22.9 +/- 2.6 microg/mL, n = 7) than in those who did not (16.0 +/- 2.1 microg/mL, n = 11, P < 0.05). Serum leptin was not associated with side effects. Circulating adiponectin may serve as an early and readily available endogenous biomarker for acute glucocorticoid-related side effects in pediatric patients.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Apr
pubmed:issn
1536-4801
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
48
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
504-6
pubmed:meshHeading
pubmed:year
2009
pubmed:articleTitle
Circulating adiponectin as a marker for glucocorticoid-related side effects in children and adolescents with inflammatory bowel disease.
pubmed:affiliation
Hospital for Children and Adolescents, University of Helsinki and Helsinki University Central Hospital, Finland. marianne.vihinen@helsinki.fi
pubmed:publicationType
Journal Article, Evaluation Studies